POLO: A randomized phase III trial of olaparib maintenance monotherapy in patients (pts) with metastatic pancreatic cancer (mPC) who have a germline BRCA1/2 mutation (gBRCAm).

被引：6
|
作者：
Golan, Talia
Oh, Do-Youn
Reni, Michele
Macarulla, Teresa Mercade
Tortora, Giampaolo
Hall, Michael J.
Reinacher-Schick, Anke C.
Borg, Christophe
Hochhauser, Daniel
Walter, Thomas
Hochster, Howard S.
Baker, Nigel
Locker, Gershon Y.
Kindler, Hedy L.
机构：
[1] Sheba Med Ctr, Oncol Inst, Tel Hashomer, Israel
[2] Seoul Natl Univ Hosp, Seoul, South Korea
[3] Hosp San Raffaele, Milan, Italy
[4] Vall Hebron Univ Hosp HUVH, Barcelona, Spain
[5] Vall Hebron Inst Oncol VHIO, Barcelona, Spain
[6] Med Sch, Verona, Italy
[7] Univ Hosp, Verona, Italy
[8] Fox Chase Canc Ctr, Philadelphia, PA USA
[9] Klinikum Ruhr Univ Bochum, St Josef Hosp, Bochum, Germany
[10] Hop Jean Minjoz, Besancon, France
[11] UCL, UCL Canc Inst, London, England
[12] Hop Edouard Herriot, Lyon, France
[13] Yale New Haven Med Ctr, 20 York St, New Haven, CT 06504 USA
[14] AstraZeneca, Cambridge, England
[15] AstraZeneca, Gaithersburg, MD USA
[16] Univ Chicago, Chicago, IL 60637 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.TPS4152
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS4152
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation
    Kaufman, Bella
    Shapira-Frommer, Ronnie
    Schmutzler, Rita K.
    Audeh, M. William
    Friedlander, Michael
    Balmana, Judith
    Mitchell, Gillian
    Fried, Georgeta
    Stemmer, Salomon M.
    Hubert, Ayala
    Rosengarten, Ora
    Steiner, Mariana
    Loman, Niklas
    Bowen, Karin
    Fielding, Anitra
    Domchek, Susan M.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03) : 244 - 250
  • [22] Olaparib as Maintenance Treatment Following First-line Platinum-based Chemotherapy (PBC) in Patients With a Germline BRCA Mutation and Metastatic Pancreatic Cancer (mPC): Phase III POLO Trial
    Golan, T.
    Hammel, P.
    Reni, M.
    Van Cutsem, E.
    Macarulla, T.
    Hall, M. J.
    Park, J. O.
    Hochhauser, D.
    Arnold, D.
    Oh, D. Y.
    Reinacher-Schick, A.
    Tortora, G.
    Alguel, H.
    O'Reilly, E. M.
    McGuinness, D.
    Cui, K. Y.
    Schlienger, K.
    Locker, G. Y.
    Kindler, H. L.
    PANCREAS, 2019, 48 (10) : 1433 - 1434
  • [23] POLO: patient-centred outcomes with maintenance olaparib in patients with a germline BRCA mutation and metastatic pancreatic cancer
    Arnold, D.
    Yoo, Kyoo H.
    Kindler, H. L.
    McGuinness, D.
    Cui, K. Y.
    Joo, S.
    Golan, T.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 224 - 224
  • [24] POLO: Patient-centred outcomes with maintenance olaparib in patients with a germline BRCA mutation and metastatic pancreatic cancer
    Kindler, H.
    Yoo, H.
    McGuinness, D.
    Cui, K.
    Joo, S.
    Locker, G.
    Golan, T.
    ANNALS OF ONCOLOGY, 2021, 32 : S134 - S134
  • [25] SOLO3: A randomized phase III trial of olaparib versuschemotherapy in platinum-sensitive relapsed ovarian cancer patients with a germline BRCA1/2 mutation (gBRCAm).
    Lowe, Elizabeth S.
    Jayawardene, Deepthi
    Penson, Richard T.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [26] Olaparib as maintenance treatment following first-line platinum-based chemotherapy in patients with a germline BRCA mutation and metastatic pancreatic cancer phase III POLO trial
    Golan, T.
    Hammel, P.
    Reni, M.
    Van Cutsen, E.
    Macarulla, T.
    Hall, M.
    Park, J.
    Hochhauser, D.
    Arnold, D.
    Oh, D.
    Reinacher-Shick, A.
    Tortora, G.
    Alguel, H.
    O'Reilly, E.
    McGuinness, D.
    Cui, K.
    Schlienger, K.
    Locker, G.
    Kindler, H.
    ANNALS OF ONCOLOGY, 2019, 30
  • [27] Olaparib sensitivity observed in metastatic pancreatic cancer (mPaC) with a wide spectrum of germline BRCA1 and BRCA2 mutations (gBRCAm).
    Golan, Talia
    Kindler, Hedy L.
    Schatz, Philipp
    Goranova, Teodora
    Locker, Gershon Y.
    Cui, Karen
    Schlienger, Katia
    McGuinness, David
    Williams, J. Andrew
    Orr, Maria
    Gutjahr, Thorsten
    Liu, Yu-Zhen
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [28] Olaparib sensitivity observed in metastatic pancreatic cancer (mPaC) with a wide spectrum of germline BRCA1 and BRCA2 mutations (gBRCAm).
    Golan, Talia
    Kindler, Hedy L.
    Schatz, Philipp
    Goranova, Teodora
    Locker, Gershon Y.
    Cui, Karen
    Schlienger, Katia
    McGuinness, David
    Williams, Andrew J.
    Orr, Maria
    Gutjahr, Thorsten
    Liu Yu-Zhen
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [29] Olaparib sensitivity observed in metastatic pancreatic cancer (mPaC) with a wide spectrum of germline BRCA1 and BRCA2 mutations (gBRCAm)
    Reinacher-Schick, A.
    Golan, T.
    Kindler, H. L.
    Schatz, P.
    Goranova, T.
    Locker, G. Y.
    Cui, K.
    Schlienger, K.
    McGuinness, D.
    Williams, J. A.
    Orr, M.
    Gutjahr, T.
    Liu, Y-Z
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 214 - 215
  • [30] POLO: Patient-Centered Outcomes With Maintenance Olaparib in PatientsWith a Germline BRCA Mutation and Metastatic Pancreatic Cancer
    Kindler, H. L.
    Yoo, H.
    McGuinness, D.
    Cui, K. Y.
    Joo, S.
    Locker, G. Y.
    Golan, T.
    PANCREAS, 2021, 50 (07) : 1071 - 1071
12345